Research programe: bile acid modulator - Albireo
Latest Information Update: 12 Jan 2017
At a glance
- Originator Albireo
- Developer Albireo Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 18 Jul 2016 Preclinical trials in Non-alcoholic steatohepatitis in Sweden (unspecified route)